In addition to outcomes, additional data will be recorded at baseline to help characterise the population. These include age, sex, body mass index, respiratory rate and peak expiratory flow (L/min). The patient’s education and work level will be characterised by the highest educational level achieved and socioprofessional category. Substance usage will be characterised by smoking (never, former, current, pack years), alcohol consumption and consumption of other substances (cannabis, opiates, amphetamines, cocaine, other (with open description)).
The patient’s asthma history and severity will be described using the month and year of first asthma symptoms and initial asthma diagnosis, global initiative for asthma (GINA) level of severity, premenstrual asthma and the maximum methacholine dose from previous methacholine testing. If performed during routine care, the fraction exhaled nitric oxide (FENO; ppb) will be recorded. The highest known blood eosinophil count for the patient will be recovered, as well as the results for the most recent skin prick test. A list of comorbidities will also be recorded for each patient.
Finally, prior experience with patient therapeutic education (and specifically for asthma) will be indicated, as well as psychometric characteristics (via the questionnaires BFI, HADS, WCC for an ancillary study).